Roivant Sciences Ltd. — Form 8-K
Filed October 21, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Roivant/Priovant announced positive Phase 3 CLARITY-1 and CLARITY-2 results for brepocitinib 45 mg in non-infectious uveitis (NIU): met primary endpoint (time to treatment failure; hazard ratios 0.27 and 0.22 vs. placebo; p<0.0001 both studies) and all key secondary endpoints. Pooled data: 62% vs. 20% achieved steroid-free quiescence at Week 48 (p<0.0001); median time to failure >48 weeks vs. ~12 weeks on placebo. Priovant plans supplemental NDA filing in H1 2027. Safety profile consistent with prior trials; no new signals. No specific financial figures disclosed.
Why this rating
Positive Phase 3 data significantly de-risks lead asset in new indication. NIU is ~70K–190K US patients; limited treatment options. sNDA filing path clear. Brepocitinib already approved (dermatomyositis). Meaningful expansion of commercial opportunity, though dollar impact not quantified. Relative to $9.8B market cap, de-risking of major pipeline asset is material.
Price action (we called it positive)
before filing · preread $37.56 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.